Avantra Biosciences this week introduced a Rapid Assay Prototyping Service. The company allows researchers to design quantitative multiplex protein assays for use on its QPDx BioChip platform.
To provide its service, Avantra relies on pre-validated antibody pairs that can be further optimized for specific research needs. In addition, Avantra said it can design QPDx assays that use a client's own immunoassay reagents. The assays can be used for screening drug targets, pathway analysis, and disease state biomarker profiling.